NCT03182244 2026-02-06
A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation
Astellas Pharma Inc
Phase 3 Active not recruiting
Clinical Trials
59 trialsNCT04240002 2026-01-05
A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
Astellas Pharma Inc
Phase 1/2 Terminated
NCT02421939 2025-12-04
A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
Astellas Pharma Inc
Phase 3 Completed
NCT03589326 2025-11-26
A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia
Takeda
Phase 3 Active not recruiting
NCT03069352 2025-09-30
A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy
AbbVie
Phase 3 Completed
NCT03860844 2025-09-09
ISAKIDS
Sanofi
Phase 2 Terminated
NCT02310321 2025-09-02
A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia.
Astellas Pharma Inc
Phase 1/2 Completed
NCT02719574 2025-06-26
Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation
Novo Nordisk A/S
Phase 1/2 Completed
NCT02303821 2025-06-04
Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia
Amgen
Phase 1 Completed
NCT03384654 2025-05-25
A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Janssen Research & Development, LLC
Phase 2 Completed
NCT02577406 2025-05-18
IDHENTIFY
Celgene
Phase 3 Completed
NCT04778410 2025-03-20
Study of Magrolimab Combinations in Participants With Myeloid Malignancies
Gilead Sciences
Phase 2 Terminated
NCT02834390 2025-03-05
Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Daiichi Sankyo
Phase 1 Completed
NCT02038777 2025-02-26
A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies
Pfizer
Phase 1 Completed
NCT04778397 2025-02-05
ENHANCE-2
Gilead Sciences
Phase 3 Terminated
NCT04029688 2024-12-20
A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors
Hoffmann-La Roche
Phase 1/2 Terminated
NCT02488408 2024-12-19
A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS
BerGenBio ASA
Phase 1/2 Completed
NCT01838395 2024-09-19
Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients
BioLineRx, Ltd.
Phase 2 Completed
NCT02668653 2024-08-06
QuANTUM-First
Daiichi Sankyo
Phase 3 Completed
NCT02400281 2024-07-03
Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients
Arog Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT01626664 2024-04-25
KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)
Kyowa Kirin Co., Ltd.
Phase 2 Completed
NCT03379727 2024-02-29
Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 (FLT3) Kinase Receptor-mutated Acute Myeloid Leukemia.
Novartis
Phase 3 Completed
NCT05020665 2024-01-10
Entospletinib Plus Intensive Induction/Consolidation Chemotherapy in Newly Diagnosed NPM1-mutated AML
Kronos Bio
Phase 3 Terminated
NCT02626338 2023-12-20
Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML
Arog Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT02520011 2023-11-15
Alvocidib Biomarker-driven Phase 2 AML Study
Sumitomo Pharma America, Inc.
Phase 2 Terminated
NCT03298984 2023-11-15
Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).
Sumitomo Pharma America, Inc.
Phase 1 Completed
NCT03969420 2023-11-09
Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination Therapy
Sumitomo Pharma America, Inc.
Phase 2 Terminated
NCT00804856 2023-10-03
Phase I/IIa Trial to Investigate BI 6727 (Volasertib) as Monotherapy or in Combination With Cytarabine in Acute Myeloid Leukaemia
Boehringer Ingelheim
Phase 2 Completed
NCT02873338 2023-09-07
Dociparstat Sodium (CX-01) Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia
Jazz Pharmaceuticals
Phase 2 Completed
NCT03416179 2023-04-21
BRIGHT AML1019
Pfizer
Phase 3 Completed
NCT03303339 2023-02-27
Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML)
Cardiff Oncology
Phase 1/2 Completed
NCT01721876 2023-02-08
Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2)
Boehringer Ingelheim
Phase 3 Completed
NCT03504410 2023-02-08
Efficacy/Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. in Older Patients With R/R AML
Cornerstone Pharmaceuticals
Phase 3 Terminated
NCT02088541 2023-01-26
SOPRA
Karyopharm Therapeutics Inc
Phase 2 Completed
NCT02287233 2022-08-29
A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acute Myelogenous Leukemia
AbbVie
Phase 1/2 Completed
NCT03850535 2022-06-21
A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission
Hoffmann-La Roche
Phase 1/2 Terminated
NCT02545283 2022-01-11
MIRROS
Hoffmann-La Roche
Phase 3 Terminated
NCT02305563 2021-09-16
An Investigational Immuno-therapy Study of Ulocuplumab in Combination With Low Dose Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia
Bristol-Myers Squibb
Phase 1/2 Terminated
NCT01696084 2020-08-10
301
Jazz Pharmaceuticals
Phase 3 Completed
NCT03135028 2020-03-06
Japanese AML
Gilead Sciences
Phase 1 Terminated
NCT01546038 2020-03-03
A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Pfizer
Phase 2 Completed
NCT02954653 2019-11-21
A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia
Pfizer
Phase 1 Terminated
NCT02343939 2019-11-15
ENTO in AML
Gilead Sciences
Phase 1/2 Terminated
NCT00875667 2019-09-16
Sprint
Celgene
Phase 2 Completed
NCT00260832 2019-09-11
Trial of Decitabine in Patients With Acute Myeloid Leukemia
Eisai Inc.
Phase 3 Completed
NCT01890746 2019-09-11
A Safety and Efficacy Study of Eltrombopag in Subjects With AML
Novartis
Phase 2 Completed
NCT00620321 2019-09-09
A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Eli Lilly and Company
Phase 2 Completed
NCT01564784 2019-01-09
A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia
Pfizer
Phase 3 Completed
NCT00780143 2018-11-09
Clinical Study of Plitidepsin (Aplidin®) in Combination With Cytarabine in Patients With Relapsed/Refractory Leukemia
PharmaMar
Phase 1/2 Terminated
NCT00907517 2018-08-27
Study of SCH 900776 (MK-8776) With and Without Cytarabine in Participants With Acute Leukemias (P05247)
Merck Sharp & Dohme LLC
Phase 1 Terminated